Table of Contents Author Guidelines Submit a Manuscript
Volume 10 (2010), Pages 2367-2384
Review Article

The Role of the TGF-β Coreceptor Endoglin in Cancer

1Instituto de Investigaciones Biomédicas Alberto Sols, Consejo Superior de Investigaciones Científicas (CSIC)-Universidad Autênoma de Madrid, Madrid, Spain
2Institute for Medical Research, University of Belgrado, Belgrado, Serbia
3Instituto Reina Sofía de Investigaciên Nefrolêgica, Departamento de Fisiologia y Farmacología, Universidad de Salamanca, Salamanca, Spain
4Centro de Investigaciones Biológicas, CSIC, and CIBER de Enfermedades Raras (CIBERER), Madrid, Spain

Received 24 June 2010; Revised 4 November 2010; Accepted 16 November 2010

Academic Editor: Adele Murrell

Copyright © 2010 Eduardo Pérez-Gómez et al.


Endoglin (CD105) is an auxiliary membrane receptor of transforming growth factor beta (TGF-β) that interacts with type I and type II TGF-β receptors and modulates TGF-β signaling. Endoglin is overexpressed in the tumor-associated vascular endothelium, where it modulates angiogenesis. This feature makes endoglin a promising target for antiangiogenic cancer therapy. In addition, recent studies on human and experimental models of carcinogenesis point to an important tumor cell–autonomous role of endoglin by regulating proliferation, migration, invasion, and metastasis. These studies suggest that endoglin behaves as a suppressor of malignancy in experimental and human epithelial carcinogenesis, although it can also promote metastasis in other types of cancer. In this review, we evaluate the implication of endoglin in tumor development underlying studies developed in our laboratories in recent years.